The financial report is the main basis for evaluating the financial status, profitability and operating conditions of an enterprise, and is an important tool for investors to understand the operation of the enterprise and make investment decisions. Not long ago, Yiling's financial report was released in the first three quarters of 2023, and good results have been achieved in both sales performance and brand building, which depend on the company's strong innovation ability and accurate industrial layout.
At the level of theoretical innovation, Yiling Pharmaceutical has systematically constructed a theoretical system of network disease, which has become the fourth milestone in the history of the development of traditional Chinese medicine. In 2006, "Theory of Complex Disease and Its Application Research" won the second prize of the National Science and Technology Progress Award, becoming a major innovative achievement in the basic theory of traditional Chinese medicine since the founding of the People's Republic of China. In 2014, the "Diagnosis and Treatment Methods of Traditional Chinese Medicine" was included in the list of China's national intangible cultural heritage; In May 2023, "Traditional Chinese Medicine Complex Disease" became a high-level key discipline construction project of Chinese medicine by the State Administration of Traditional Chinese Medicine of China. In December 2023, the "6th Qihuang Forum" was held in Beijing, at which the landmark scientific and technological achievements of traditional Chinese medicine in the new era (2012-2022) were released.
According to Yiling's financial report, Yiling Pharmaceutical has also continuously increased investment in scientific research and innovation, built a national enterprise technology center, a national key laboratory, a national local joint engineering laboratory and other innovation platforms, with 2,000 scientific research personnel, and has undertaken more than 60 national projects such as major new drug creation projects, and won 1 first prize of National Science and Technology Progress Award, 1 second prize of National Technological Invention Award, and 4 second prizes of National Science and Technology Progress Award. In terms of product innovation, Yiling Pharmaceutical has developed innovative patented traditional Chinese medicines such as Tongxinluo Capsule, Ginseng Song Yangxin Capsule, Lianhua Qingwen Capsule Granules, etc., covering cardiovascular and cerebrovascular diseases, respiratory diseases, diabetes, tumors and other clinical frequent and major diseases, and has obtained registration approvals and market sales in more than 50 countries and regions.
In addition, Yiling's financial report also shows that while carrying out innovative traditional Chinese medicine business, Yiling Pharmaceutical also actively lays out chemical drugs, biological drugs and health industries, and builds a pharmaceutical and health industry pattern of coordinated development and mutual promotion of patented traditional Chinese medicine, chemical and biological drugs, and health industries. In terms of innovative chemical drugs, Yiling Pharmaceutical has four first-class innovative drugs in the clinical stage, and a number of first-class innovative drugs are in the preclinical research stage. Among them, chemical drugs for postoperative analgesia 1The Class 1 new drug anilineprofen injection is about to be put into production, and if it is successfully approved, it will not only become the company's first approved chemical drug1Class 1 new drugs will also further enhance the company's competitiveness in the market of neurochemical drugs (including biological drugs). In the health industry sector, Yiling Pharmaceutical, with its subsidiary Yiling Health, is the main operating platform of the health sector to build a health industry structure - covering Shijiazhuang Yiling Health City, Yiling Health E-commerce, Yiling Pharmacy Chain and other business sectors, and highly integrate the R&D, sales and service system of health products.
Therefore, it can be seen from Yiling's financial report that the company has not only made a major breakthrough in the theoretical innovation of traditional Chinese medicine, but also successfully developed a series of innovative patented traditional Chinese medicines by building an innovation platform and increasing investment in scientific research, providing effective solutions for the field of clinical frequent and major diseases. At the same time, Yiling Pharmaceutical has also actively laid out the chemical and biological drugs and health industries, further consolidating its leading position in the industry.